Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

ConferencetegavivintPositive

AI Analysis

Summary

Iterion Therapeutics will present Phase 1/2 data on tegavivint for advanced hepatocellular carcinoma as an oral presentation at the 2026 ASCO Annual Meeting, with two additional investigator-sponsored trial posters featuring tegavivint studies in EGFR-mutated NSCLC and pediatric osteosarcoma.

Clinical Trial Data

Phase

1/2

Outcome Details

Oral presentation of Phase 1/2 tegavivint data in advanced hepatocellular carcinoma; two investigator-sponsored trial posters on tegavivint in EGFR-mutated NSCLC and pediatric osteosarcoma

Importance:5/10

Sentiment:

0.50

tegavivinthepatocellular carcinomaNSCLCosteosarcomaASCO 2026clinical data presentation

Read the original article

Published by PR Newswire Biotech on May 4, 2026 12:09 PM

Read Original